Situation: A 61-year-old woman with lung cancer that has spread to the bones is admitted to the oncology ward for symptom control. Her goal is to stay comfortable. She receives subcutaneous denosumab every 4 weeks for her bone metastases, and a dose is due on admission. Before giving it, the nurse reviews these findings: Serum calcium: 7.8 mg/dL (8.6–10.2); serum albumin 4.1 g/dL (3.5–5.0) Hemoglobin: 10.8 g/dL (12.0–16.0) Mouth: routine dental check 5 months ago; no tooth pain, loose teeth, or exposed bone Pain: 6 out of 10 in the hips on her usual analgesics Which finding is MOST important to report before the dose is given?

Denosumab blocks bone resorption and can cause severe hypocalcemia, so calcium is checked and corrected before each dose. Her calcium of 7.8 mg/dL with a normal albumin is truly low, so the nurse holds the dose and reports it for replacement. Osteonecrosis of the jaw is prevented by dental review before starting and good oral hygiene, and she has no warning signs; anemia and bone pain do not make the dose unsafe.

Why calcium is the priority
Denosumab is a monoclonal antibody that binds RANKL and prevents it from activating osteoclasts. Because osteoclast-mediated bone resorption is suppressed, calcium efflux from bone into the bloodstream drops sharply. In a patient who already has low calcium, giving the next dose can push the level dangerously lower and trigger tetany, seizures, or arrhythmias. A total calcium of 7.8 mg/dL with a normal albumin of 4.1 g/dL represents true hypocalcemia, not a laboratory artifact from low protein. The dose should be held and the calcium deficit corrected before denosumab is administered.

How denosumab causes hypocalcemia
Under normal conditions, osteoclasts resorb bone and release calcium into the extracellular fluid. Denosumab blocks this pathway, so the skeleton stops contributing calcium to the serum pool. Patients with normal renal function and adequate vitamin D can compensate by increasing intestinal calcium absorption and renal calcium reabsorption, but compensation is incomplete when baseline calcium is already low. The risk is greatest in patients with reduced renal function, because the kidney cannot generate sufficient active vitamin D or retain calcium effectively. Even in patients without advanced kidney disease, pre-existing hypocalcemia is an independent reason to withhold the dose.

Interpreting the calcium value with albumin
Total serum calcium includes both protein-bound and ionized fractions. When albumin is low, total calcium may appear low even though the physiologically active ionized calcium is normal. This patient’s albumin is normal, so no correction formula is needed. Key point! A low total calcium with normal albumin should be treated as true hypocalcemia. The ionized calcium would be expected to be low as well, which is the fraction responsible for neuromuscular stability.

Comparing the other findings

Finding	Why it is not the priority
Hemoglobin 10.8 g/dL	Mild anemia is common in advanced cancer and does not contraindicate denosumab. It requires monitoring but does not make this dose unsafe.
Dental check 5 months ago	Osteonecrosis of the jaw is a concern with denosumab, but prevention focuses on dental evaluation before starting therapy and ongoing oral hygiene. This patient has no tooth pain, loose teeth, or exposed bone, so there is no acute contraindication.
Hip pain 6/10	Bone pain from metastases is expected and is part of why the patient is receiving denosumab. Pain alone does not make the dose unsafe; it supports the need for continued bone-targeted therapy once calcium is corrected.

Timing and monitoring around denosumab
Calcium should be checked before each dose, and the result must be reviewed before the injection is given. If hypocalcemia is present, replacement with calcium and vitamin D is initiated first, and the denosumab dose is delayed until the level is acceptable. The hypocalcemia risk is not limited to the first dose; subsequent doses can also lower serum calcium, especially when renal function is impaired or baseline calcium is borderline. In this patient, the calcium of 7.8 mg/dL is below the lower limit of normal and must be corrected before the scheduled dose proceeds.

Clinical priority in the oncology ward
This patient’s stated goal is comfort. Giving denosumab while hypocalcemic could produce acute symptoms such as perioral numbness, muscle cramps, carpopedal spasm, or laryngospasm, which would directly undermine that goal. Watch out! Hypocalcemia can progress silently until neuromuscular irritability appears, so the laboratory value is the most important finding to act on before the dose. The hemoglobin, dental history, and hip pain are all relevant to overall care but none of them creates an immediate risk from the denosumab injection itself.